Aware that further testing in randomized clinical trials is warranted, we propose that nivolumab with and following CRT may prove beneficial in LACC patients, whose tumors display a brisk, pretreatment immune infiltrate in the proximity of PD-L1+ tumor cells, activated, tumor-infiltrating T and myeloid cells along with enrichment in IFN-related pathways. The gene discussed is CD274; the disease is neoplasm.